An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.
Case: A 73-Year-Old Man with EGFR+ NSCLC
Clinical Presentation:
Past Medical History:
Social History:
Initial Clinical Workup and Diagnosis:
Physical Examination
Pulmonary Function Tests
Imaging Studies:
Diagnostic Procedure:
Neoadjuvant Therapy and Surgical Resection:
Surgical Pathology Report:
Six Months Later:
Second Line Systemic Therapy:
Repeat Imaging at 8 Weeks:
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Joshua K. Sabari, MD.
This video features a discussion on the recent phase 3 MARIPOSA trial results of the antibody-drug conjugate amivantamab plus the third-generation EGFR tyrosine kinase inhibitor lazertinib for the first-line treatment of EGFR-mutated non–small cell lung cancer (NSCLC). The trial compared amivantamab-lazertinib to osimertinib monotherapy and lazertinib monotherapy.
The amivantamab-lazertinib combination demonstrated nearly a 24-month median progression-free survival benefit over 16-17 months with osimertinib. Toxicities were manageable but increased, including more skin rash, venous thromboembolism requiring anticoagulation, and infusion reactions with amivantamab plus lazertinib.
Overall survival data is still immature, but a hazard ratio of 0.8 suggests potential for sustained benefit. Routine brain MRI was done and removing central nervous system progressions extended median progression-free survival to 28 to 29 months with the amivantamab-lazertinib combination.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More